Policy & Regulation
4basebio secures clinical supply agreement for Phase II immunotherapy trial
20 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to prov...
FDA approves MEKanistic Therapeutics' IND for MTX-531
20 May 2026 - Biotechnology company MEKanistic Therapeutics announced on Tuesday that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug application for MTX-531, its le...
Sino Biological launches XPressMAX Cell-Free Protein Synthesis Kit
20 May 2026 - Recombinant technology specialist Sino Biological Inc (SZ:301047) announced on Tuesday the launch of its XPressMAX Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), designed to supercharg...
Matter Bio submits first IND application for Lm-LLO-TT
20 May 2026 - Biotechnology company Matter Bio announced on Tuesday the submission of its first Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for Lm-LLO-TT fo...
Myosin Therapeutics doses first patient in Phase 1/2 study of MT-125 in GBM
20 May 2026 - Myosin Therapeutics, a clinical stage biotechnology company developing therapies for oncology, announced on Tuesday that the first patient has been dosed in the Phase 1/2 STAR-GBM study ...
Nanjing Leads Biolabs receives Chinese approval for pivotal Phase III trial of PD-L1/4-1BB bispecific antibody
19 May 2026 - Clinical-stage biotechnology company Nanjing Leads Biolabs Co Ltd (HK:9887) announced on Monday that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received...